All In Biotech

Free tool

FAERS Monitor: Tofidence

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761354 or its brand name (Tofidence, Tocilizumab-Bavi). Reports on generic versions are filed under their own applications.

Reports

31,081

Serious

29,571

95% of reports

Hospitalization

13,341

Death reported

6,642

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use9,475
  • drug ineffective7,201
  • rheumatoid arthritis5,112
  • pain4,584
  • fatigue3,997
  • rash3,915
  • contraindicated product administered3,630
  • drug intolerance3,389
  • arthropathy3,343
  • product use issue3,272
  • alopecia3,265
  • arthralgia3,261
  • treatment failure3,252
  • systemic lupus erythematosus3,251
  • hypersensitivity3,199

Reports by year received

View as table
YearReports
200611
20074
20082
200910
2010520
2011424
2012512
2013663
2014449
2015474
2016617
2017751
20181,218
20191,328
20203,306
20214,517
20224,692
20233,479
20243,519
20252,789
20261,796

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,078 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
contraindicated product administeredSignal3,63092.089.1288,053
systemic lupus erythematosusSignal3,25168.165.8195,617
arthropathySignal3,34343.241.8129,938
rheumatoid arthritisSignal5,11231.931.0146,688
treatment failureSignal3,25227.626.780,414
drug intoleranceSignal3,38924.623.874,248
product use issueSignal3,27212.011.632,611
hypersensitivitySignal3,19911.811.531,497
alopeciaSignal3,26511.411.130,817
off label useSignal9,4757.47.354,045
rashSignal3,9156.15.916,980
arthralgiaSignal3,2615.35.211,643
painSignal4,5845.14.915,355
drug ineffectiveSignal7,2013.73.615,138
fatigueSignal3,9973.53.47,322

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.